Latest On Grifols, S.A (GIKLY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 09:57 EST | News | Grifols, S.A. (GRFS) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-10 09:57 EST | News | Grifols, S.A. 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-05-09 21:07 EST | News | Grifols S.A. reports Q1 results; raises FY23 guidance | N/A | |
| 2023-05-08 18:11 EST | News | Grifols names new CEO ending founding family’s leadership | N/A | |
| 2023-03-06 22:18 EST | News | Grifols, Selagine team up to develop immunoglobulin eye drops | N/A | |
| 2023-03-01 04:17 EST | News | Grifols, S.A. (GRFS) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-01 04:17 EST | News | Grifols, S.A. 2022 Q4 - Results - Earnings Call Presentation | N/A | |
| 2023-02-15 18:41 EST | News | Grifols cuts 8% staff mainly in U.S. as cost savings plan takes effect | N/A | |
| 2022-03-15 13:10 EST | News | Grifols ABvac40 vaccine for Alzheimer's shows safety/response in phase 2 interim data | N/A | |
| 2022-02-10 19:39 EST | News | Grifols: Short-Term Turbulence But Long-Term Upside | N/A | |
| 2022-02-07 14:34 EST | News | Grifols extends losses as JPMorgan points to downside risk to consensus | N/A | |
| 2021-08-11 12:31 EST | News | GigaGen gets dosing underway in early-stage GIGA-2050 COVID-19 trial | N/A | |
| 2021-07-22 12:34 EST | News | Grifols launches hepatitis B treatment HyperHEP B | N/A | |
| 2021-07-22 12:33 EST | News | Grifols presents at 2021 investor and analyst day - slideshow | N/A | |
| 2021-07-22 12:28 EST | News | Grifols: Valuation Discount Remains Wide Despite An Upbeat Capital Markets Day | N/A | |
| 2021-07-22 12:27 EST | News | GigaGen says novel mechanism of cancer candidate support superior anti-tumor activity | N/A | |
| 2021-06-03 06:11 EST | Dividend | A dividend of $0.22 has been announced on Nov 30, -0001. It will be paid Jun 14, 2021 with an ex-dividend date of Jun 3, 2021. | Neutral | |
| 2021-04-20 15:49 EST | News | Grifols: The Plasma-Supply Disruption Provides An Attractive Entry Point | N/A | |
| 2021-03-02 09:09 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-19 06:09 EST | News | Grifols to trial new immunoglobulin therapy against COVID-19 | N/A | |
| 2020-11-26 22:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 05:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 14:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 14:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-01 06:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 22:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 07:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 02:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 07:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 18:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 22:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-08 14:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 22:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-25 22:15 EST | Financials | Company financials have been released. | Neutral | |
About Grifols, S.A (GIKLY):
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
General
- Name Grifols, S.A
- Symbol GIKLY
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 23,655
- Last Split Factor2:1
- Last Split Date2016-01-04
- Fiscal Year EndDecember
- Web URLhttp://www.grifols.com
View More
Valuation
- Trailing PE 20.18
- Forward PE 18.05
- Price/Sales (Trailing 12 Mt.) 2.61
- Price/Book (Most Recent Quarter) 2.72
- Enterprise Value Revenue 4.17
- Enterprise Value EBITDA 15.63
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 12%
- Return on Assets 5%
- Return on Equity 10%
- Earnings Per Share $0.60
- Revenue Per Share $0
- Gross Profit 2.51 billion
- Quarterly Earnings Growth -3.8%
View More
Highlights
- Market Capitalization 15.28 billion
- PE Ratio 25.47
- PEG Ratio 2.68
- Analyst Target Price $55.5
- Book Value Per Share $3.56
View More
Share Statistics
- Shares Outstanding 1.37 billion
- Shares Float 856.69 million
- % Held by Insiders <1%
View More
Technicals
- Beta 0.05
- 52 Week High $17.72
- 52 Week Low $12
- 50 Day Moving Average 13.63
- 200 Day Moving Average 14.39
View More
Dividends
- Forward Annual Dividend Rate $0.19
- Forward Annual Dividend Yield 1.57%
- Payout Ratio 13%
- Dividend Date 2020-11-09
- ExDividend Date 2020-10-30
- Dividend Per Share $0.47
- Dividend Yield 0%
View More
Grifols, S.A (GIKLY) Dividend Calendar:
GIKLY's last dividend payment was made to shareholders on November 9, 2020.
Grifols, S.A pays out 13% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Grifols, S.A (GIKLY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $0.23 | ||
| 2020-06-30 | 2020-09-30 | $1.38 billion | $0.46 | ||
| 2020-03-31 | 2020-06-30 | $1.29 billion | $0.06 | ||
| 2019-12-31 | 2020-03-31 | $1.36 billion | $0.30 | ||
| 2019-09-30 | 2019-12-31 | $1.31 billion | $0.32 | ||
| 2019-06-30 | 2019-09-30 | $1.27 billion | $0.22 | ||
| 2019-03-31 | 2019-06-30 | $1.16 billion | $0.28 | ||
| 2018-12-31 | 2019-03-31 | $1.22 billion | $0.19 | ||
| 2018-09-30 | 2018-12-31 | $833.8 million | $0.21 | ||
| 2018-06-30 | 2018-09-30 | $1.1 billion | $0.26 | ||
| 2018-03-31 | 2018-06-30 | $1.02 billion | $0.30 | ||
| 2017-12-31 | 2018-03-31 | $798.66 million | $0.26 | ||
| 2017-09-30 | 2017-12-31 | $1.06 billion | $0.41 | ||
| 2017-06-30 | 2017-09-30 | $1.13 billion | $0.26 | ||
| 2017-03-31 | 2017-06-30 | $1.06 billion | $0.24 | ||
| 2016-12-31 | 2017-03-31 | $1.1 billion | $0.21 | ||
| 2016-09-30 | 2016-12-31 | $0.22 | |||
| 2016-06-30 | 2016-09-30 | $0.24 | |||
| 2016-03-31 | 2016-06-30 | $0.22 | |||
| 2015-12-31 | 2016-03-31 | $0.21 | |||
| 2015-09-30 | 2015-12-31 | $0.20 | |||
| 2015-06-30 | 2015-09-30 | $0.22 | |||
| 2015-03-31 | 2015-06-30 | $0.21 | |||
| 2014-12-31 | 2015-03-31 | $0.20 | |||
| 2014-09-30 | 2014-12-31 | $0.23 | |||
| 2014-06-30 | 2014-09-30 | $0.21 | |||
| 2014-03-31 | 2014-06-30 | $0.21 | |||
| 2013-12-31 | 2014-03-31 | $0.24 | |||
| 2013-09-30 | 2013-12-31 | $0.15 | |||
| 2013-06-30 | 2013-09-30 | $0.17 | |||
| 2013-03-31 | 2013-06-30 | $0.18 | |||
| 2012-12-31 | 2013-03-31 | $0.17 | |||
| 2012-09-30 | 2012-12-31 | $0.11 | |||
| 2012-06-30 | 2012-09-30 | $0.12 | |||
| 2012-03-31 | 2012-06-30 | $0.12 | |||
| 2011-12-31 | 2012-03-31 | $0.13 | |||
| 2011-09-30 | 2011-12-31 | $0.01 | |||
| 2011-06-30 | 2011-09-30 | $0.05 | |||
| 2011-03-31 | 2011-06-30 | -$0.04 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.11 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.06 | $0.00 |
Grifols, S.A (GIKLY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 80.75 million | N/A | 74.25 million | 67.87 million | 75.03 million |
| Income Before Tax | 202.63 million | N/A | 75.87 million | 251.28 million | 259.1 million |
| Selling General Administrative | 261.35 million | N/A | 233.78 million | 250.59 million | 246.65 million |
| Gross Profit | 590.53 million | N/A | 447.38 million | 591.23 million | 608.62 million |
| Ebit | 374.52 million | N/A | 211.77 million | 350.36 million | 286.94 million |
| Operating Income | 248.43 million | N/A | 139.36 million | 272.78 million | 286.94 million |
| Income Tax Expense | N/A | 62.97 million | 17.73 million | 47.74 million | 56.86 million |
| Total Revenue | 1.31 billion | N/A | 1.38 billion | 1.29 billion | 1.36 billion |
| Cost of Revenue | 718.8 million | N/A | 936.64 million | 702.09 million | 752.29 million |
| Total Other Income Expense Net | 62.34 million | N/A | -3.74 million | -4.66 million | -27.84 million |
| Net Income From Continuing Operations | 161.43 million | N/A | 58.14 million | 203.54 million | 202.24 million |
| Net Income Applicable to Common Shares | N/A | 267.44 million | 31.87 million | 186.38 million | 201.74 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -83.09 million | -109.76 million | -113.31 million | -31.82 million | 142.76 million |
| Change to Liabilities | 43.48 million | -15.83 million | -23.28 million | 26.13 million | 23.05 million |
| Total Cash Flow from Investing Activities | -83.09 million | -109.76 million | -113.31 million | -155.65 million | 38.82 million |
| Net Borrowings | -47.29 million | -56.95 million | -114.84 million | 143.81 million | -49.22 million |
| Total Cash Flow from Financial Activities | -42.81 million | -68.38 million | -110.04 million | -92.75 million | -39.41 million |
| Change to Operating Activities | 11.73 million | N/A | N/A | -13.87 million | -7.31 million |
| Change in Cash | 187.87 million | 254.4 million | -117.98 million | -50.15 million | 238.44 million |
| Total Cash from Operating Activities | 310.97 million | 435.34 million | 105.37 million | 229.73 million | 193.66 million |
| Depreciation | 80.87 million | 80.64 million | 77.57 million | 49.01 million | 75.19 million |
| Other Cash Flow from Investing Activities | -27.05 million | -9.31 million | -8.91 million | 18.93 million | -18.93 million |
| Change to Inventory | 8.58 million | 325.56 million | -74.68 million | -70.73 million | -43.48 million |
| Change to Account Receivables | N/A | N/A | 1.34 million | -85.71 million | 39.78 million |
| Other Cash Flow from Financing Activities | 4.48 million | -11.43 million | 4.8 million | -236.56 million | 9.81 million |
| Change to Net Income | -95.94 million | 95.26 million | -61.96 million | 93.83 million | -30.09 million |
| Capital Expenditures | 77.06 million | 96.64 million | 86.4 million | 121.9 million | 69.22 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 8.55 billion | 8.54 billion | 8.56 billion | 8.69 billion | 8.7 billion |
| Total Stockholder Equity | 5.11 billion | 5.35 billion | 5.36 billion | 5.54 billion | 4.82 billion |
| Other Current Liabilities | 105.04 million | 1.24 billion | 217.39 million | 1.33 billion | 151.26 million |
| Total Assets | 15.27 billion | 15.65 billion | 15.6 billion | 15.9 billion | 15.54 billion |
| Common Stock | N/A | 119.6 million | 119.6 million | 119.6 million | 119.6 million |
| Other Current Assets | 51.75 million | 43.76 million | 43.37 million | 45.93 million | 78.98 million |
| Retained Earnings | 618.55 million | 485.68 million | 218.25 million | 186.38 million | 528.09 million |
| Other Liabilities | N/A | 566.3 million | 509.85 million | 492.37 million | 544.2 million |
| Other Assets | N/A | 126.4 million | 125.03 million | 131.55 million | 564.25 million |
| Cash | 579.65 million | 1.03 billion | 878.41 million | 637.7 million | 741.98 million |
| Total Current Liabilities | 1.34 billion | 1.24 billion | 1.24 billion | 1.33 billion | 1.37 billion |
| Other Stockholder Equity | N/A | 4.01 billion | 4.3 billion | 4.51 billion | 3.31 billion |
| Property, Plant & Equipment | N/A | 2.17 billion | 2.22 billion | 2.21 billion | 2.86 billion |
| Total Current Assets | 3.16 billion | 3.64 billion | 3.55 billion | 3.66 billion | 5.36 billion |
| Long Term Investments | 2.07 billion | 2.04 billion | 2.07 billion | 2.09 billion | 143.98 million |
| Net Tangible Assets | N/A | -2.32 billion | -2.26 billion | -2.26 billion | -1.79 billion |
| Short Term Investments | 10.86 million | 12.29 million | 12.32 million | 13.04 million | 11.4 million |
| Long Term Debt | 5.9 billion | N/A | 6.09 billion | N/A | 6.09 billion |
| Inventory | 2 billion | 1.99 billion | 2.09 billion | 2.46 billion | 2.34 billion |
| Accounts Payable | 601.62 million | N/A | 551.91 million | N/A | 581.88 million |
Grifols, S.A (GIKLY) Chart:
Grifols, S.A (GIKLY) News:
Below you will find a list of latest news for Grifols, S.A (GIKLY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Grifols, S.A (GIKLY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Grifols, S.A (GIKLY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|